In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...

A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Ryan Seacrest Sparks Concern From Fans in New Photos originally appeared on Parade. Ryan Seacrest has fans worried after the Wheel of Fortune host shared some new photos via social media.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the drugmaker in a more vulnerable position when rival Eli Lilly ...

CNBC's Angelica Peebles reports on news regarding CVS. Qantas hit by cyberattack, six million customers' data potentially ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.